Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
Abstract Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tociliz...
Saved in:
Main Authors: | Haleh Rezaee (Author), Fariba Pourkarim (Author), Samira Pourtaghi‐Anvarian (Author), Taher Entezari‐Maleki (Author), Touraj Asvadi‐Kermani (Author), Masoud Nouri‐Vaskeh (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molnupiravir: A new candidate for COVID‐19 treatment
by: Fariba Pourkarim, et al.
Published: (2022) -
Clinical considerations on monkeypox antiviral medications: An overview
by: Fariba Pourkarim, et al.
Published: (2024) -
Drug Utilization Evaluation of Carbapenems in a Teaching Hospital in Tabriz-Iran
by: Taher Entezari-Maleki, et al.
Published: (2018) -
Pharmacotherapy Plays Main Role in Managing Acute Epiploic Appendagitis: A Case Report
by: Touraj Asvadi-Kermani, et al.
Published: (2020) -
Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment
by: Hamed Imanpour, et al.
Published: (2020)